Latest News and Press Releases

LAUSANNE, Switzerland, March 21, 2022 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative...

ACI-12589 distinguished multiple system atrophy (MSA) from other a-synucleinopathies and healthy volunteers A-syn PET tracers may be developed to diagnose a-synuclein pathologies, including...

Five presentations at the International Conference on Alzheimer’s & Parkinson’s Diseases (AD/PDTM) AC Immune’s Chief Medical Officer to participate in expert forum on translational drug discovery...

Observed strong induction of antibodies specific for pathological forms of Tau with ACI-35.030 treatment ACI-35.030 continues to be well tolerated with no clinically relevant safety concerns observed...

Results differentiate ACI-24 as potential best-in-class Abeta vaccine in development Strong response against neurotoxic pyroGlu-Abeta variants observed in non-human primates Data further support...

LAUSANNE, Switzerland, Feb. 02, 2022 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today...

Funding to accelerate the development of first-in-class brain penetrant small molecules to inhibit a-syn aggregation and NLRP3 inflammasome activation in Parkinson’s disease (PD) Programs targeting...

Observed strong induction of antibodies specific for pathological forms of Tau with ACI-35.030 treatment New data presented at 14th CTAD conference support ACI-35.030’s advancement into late-stage...

Analysis of the broader mITT population is consistent with the previously reported success in meeting one of the two co-primary endpoints (ADAS-Cog11) with statistically significant reduction in the...

Announced the first positive cognitive results for a Tau-targeting monoclonal antibody in mild-to-moderate Alzheimer’s disease Closed its strategic acquisition of an industry-leading Parkinson’s...